Genzyme Corporation (GENZ)’s Lemtrada® Approved In Mexico For Treatment Of Multiple Sclerosis
2/4/2014 9:44:27 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that Mexico’s national regulatory authority, COFEPRIS, has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing remitting forms of multiple sclerosis (MS) to slow or reverse the accumulation of physical disability and reduce the frequency of clinical exacerbations.
Help employers find you! Check out all the jobs and post your resume.
comments powered by